Benton Christopher B, Ravandi Farhad
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Future Oncol. 2017 Jan;13(2):125-133. doi: 10.2217/fon-2016-0300. Epub 2016 Sep 12.
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. Here, we examine vosaroxin's mechanism of action and pharmacology, and we review its use in AML to date, focusing on details of individual clinical trials. Most recently, when combined with cytarabine in a randomized Phase III trial (VALOR), vosaroxin improved outcomes versus cytarabine alone for relapsed/refractory AML in patients older than 60 years and for patients in early relapse. We consider its continued role in the context of a multifaceted strategy against AML, including its current use in clinical trials. Prospective use will define its role in the evolving landscape of AML therapy.
伏沙罗辛是一种喹诺酮类化合物，可嵌入DNA并诱导不依赖TP53的细胞凋亡，在I - III期试验中显示出对急性髓系白血病（AML）的活性。在此，我们研究伏沙罗辛的作用机制和药理学，并回顾其迄今为止在AML中的应用，重点关注个别临床试验的细节。最近，在一项随机III期试验（VALOR）中，伏沙罗辛与阿糖胞苷联合使用时，对于60岁以上复发/难治性AML患者以及早期复发患者，与单独使用阿糖胞苷相比改善了治疗结果。我们考虑其在针对AML的多方面策略背景下的持续作用，包括其目前在临床试验中的应用。前瞻性应用将确定其在AML治疗不断演变的格局中的作用。
